Last reviewed · How we verify
fenofibrate and tibolone
This combination product uses fenofibrate to lower triglycerides and raise HDL cholesterol via PPAR-alpha activation, while tibolone provides hormone replacement therapy through selective tissue-specific estrogenic, progestagenic, and androgenic activity.
This combination product uses fenofibrate to lower triglycerides and raise HDL cholesterol via PPAR-alpha activation, while tibolone provides hormone replacement therapy through selective tissue-specific estrogenic, progestagenic, and androgenic activity. Used for Hypertriglyceridemia in postmenopausal women, Menopausal symptoms with dyslipidemia.
At a glance
| Generic name | fenofibrate and tibolone |
|---|---|
| Also known as | Lipidil, Livial |
| Sponsor | Keogh Institute for Medical Research |
| Drug class | Fibrate + Selective Estrogen Receptor Modulator (SERM) |
| Target | PPAR-α (fenofibrate); Estrogen receptor, progesterone receptor, androgen receptor (tibolone) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Women's Health |
| Phase | FDA-approved |
Mechanism of action
Fenofibrate is a fibric acid derivative that activates peroxisome proliferator-activated receptor alpha (PPAR-α), increasing lipoprotein lipase activity and reducing triglyceride-rich lipoprotein production. Tibolone is a synthetic steroid that acts as a selective estrogen receptor modulator (SERM) and provides combined estrogenic, progestagenic, and weak androgenic effects for menopausal symptom relief. The combination addresses both cardiovascular lipid abnormalities and menopausal symptoms in postmenopausal women.
Approved indications
- Hypertriglyceridemia in postmenopausal women
- Menopausal symptoms with dyslipidemia
Common side effects
- Myalgia or muscle pain
- Headache
- Vaginal bleeding or spotting
- Gastrointestinal upset
- Elevated liver enzymes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fenofibrate and tibolone CI brief — competitive landscape report
- fenofibrate and tibolone updates RSS · CI watch RSS
- Keogh Institute for Medical Research portfolio CI